circPRMT5 |
Urothelial carcinoma of the Bladder |
Up |
circPRMT5/miR-30c |
EMT |
Promoting UCB cell’s EMT and aggressiveness; Serve as an exploitable therapeutic target |
[59] |
circMTO1 |
Bladder cancer |
Down |
circMTO1/miR-221 |
EMT |
Negatively regulate the E-cadherin/N-cadherin; Inhibits EMT as well as metastasis |
[60] |
circ_0023642 |
Gastric cancer |
Up |
Not mentioned |
EMT |
Promote the EMT signaling pathway; Serve as a metastasis activator and molecular therapeutic target |
[61] |
circSMAD2 |
Hepatocellular carcinoma |
Down |
circSMAD2/miR-629 |
EMT |
Impedes ability of HCC cells to migrate and invade as well as EMT |
[62] |
circAMOTL1L |
Prostate cancer |
Down |
P53/RBM25/circAMOTL1L/miR193a-5p/Pcdha |
EMT |
Suppress ability of cells to migrate and invade via lowering of E-cadherin and increasing vimentin |
[63] |
circANKS1B |
Breast cancer. |
Up |
circANKS1B/ miR-148a/152-3p/USF1 |
EMT |
Invasion and metastasis are promoted by EMT via TGF-β1 induction: however, nothing is observed for growth of breast cancer |
[64] |
circ_0061140 |
Ovarian Cancer |
Up |
circ_0061140/miR-370/FOXM1 |
EMT |
Competes with endogenous RNA of miR-370 which allows for growth of cells and metastasis |
[65] |
circMYLK |
Bladder cancer |
Up |
circMYLK/miR-29a/VEGFA/VEGFR2 |
EMT |
Contribute to EMT and the development of bladder cancer via activating VEGFA/VEGFR2 |
[66] |
circFECR1 |
Breast cancers |
Up |
circFECR1/DNMT1/TET1 |
DNA demethylation |
Interact with the FLI1 promoter; regulate metastasis by coordinating DNA methylation and demethylation |
[72] |
circIARS |
Pancreatic cancer |
Up |
circIARS/miR-122/ZO-1 |
Mediated by exosome |
Regulates the permeability of endothelial monolayer to augment the invasion and metastasis |
[79] |
circ-DB |
Hepatocellular carcinoma |
Up |
circ-DB/ miR-34a/ USP7/Cyclin A2 |
Mediated by adipose-derived exosome |
Promote the tumorigenesis of HCC |
[80] |